This early-stage study is testing a new oral drug called CFT7455 (cemsidomide) in people with advanced non-Hodgkin's lymphoma or multiple myeloma that has returned or stopped responding to standard treatments. The main goals are to find a safe dose and see if the drug can shrink …
Phase: PHASE1 • Sponsor: C4 Therapeutics, Inc. • Aim: Disease control
Last updated Mar 30, 2026 14:34 UTC